Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 20;20(1):16.
doi: 10.1186/s12860-019-0205-4.

An Electron paramagnetic resonance (EPR) spin labeling study in HT-29 Colon adenocarcinoma cells after Hypericin-mediated photodynamic therapy

Affiliations

An Electron paramagnetic resonance (EPR) spin labeling study in HT-29 Colon adenocarcinoma cells after Hypericin-mediated photodynamic therapy

D Yonar et al. BMC Mol Cell Biol. .

Abstract

Background: Colon cancer affects 1.23 million people worldwide and is the third most common malignant disease in men and the second in women. The only curative treatment is surgical resection, but a significant number of patients develop local recurrence or distant metastases. One of the alternative treatment methods for colon cancer is photodynamic therapy (PDT). In recent years, hypericin (HYP) derived from Hypericum perforatum has been suggested as a strong candidate photosensitizer for PDT. Our interest is focused on the biophysical changes in colon cancer cells in relation to HYP-mediated PDT.

Results: In this study, HYP-mediated PDT at 0.04, 0.08 or 0.15 μM HYP concentrations was performed in HT-29 colon adenocarcinoma cells and the Electron Paramagnetic Resonance (EPR) spectra of the spin labeled cells were obtained. Plasma membranes are already heterogeneous structures; the presence of cancer cells increased the heterogeneity and also fluidity of the plasma membranes. Therefore, the obtained spectra were evaluated by EPRSIMC program, which provides the calculation of heterogeneous structures up to four spectral components with different fluidity characteristics. Generally, two motional patterns were obtained from calculations and the number of them increased at the highest concentration. As the order parameters of the most populated components compared, an increase was observed depending on the HYP concentration. However, because of the heterogeneous structure of membrane, the order parameters of the less populated components did not exhibit a regular distribution.

Conclusion: After HYP-mediated PDT, concentration dependent changes were observed in the domain parameters indicating an increase in the HYP accumulation.

Keywords: EPR spin labeling; Hypericin; Membrane fluidity; Photodynamic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structure of hypericin
Fig. 2
Fig. 2
Experimental (black lines) and calculated spectra (colored lines) of 16-DS spin labeled control and HYP mediated HT-29 cells at a) 298 K, b) 310 K
Fig. 3
Fig. 3
Concentration dependent change in the order parameter of HT-29 colon cancer cells at 298 and 310 K
Fig. 4
Fig. 4
Examples of the GHOST diagrams, defined by the RGB specification where the intensity of each color component (red, green, and blue, respectively) represents the relative value of the spectral parameters (τc, W, pa), for control and HYP treated HT-29 cells at 298 K. The red points show the weighted mean and peripheral colored points show the distribution of solutions
Fig. 5
Fig. 5
Concentration dependent change in the rotational correlation time (τc) of spin label in HT-29 colon cancer cells at 298 and 310 K: a) from computer simulation, b) calculated from direct evaluation of spectra. The degree of significance was denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 with respect to control sample
Fig. 6
Fig. 6
Experimental, calculated, and domain spectra of 16-DS spin labeled 0.4 μM HYP mediated HT-29 cells at a) 298 K and b) 310 K

References

    1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–548. doi: 10.1001/jamaoncol.2016.5688. - DOI - PMC - PubMed
    1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–281. doi: 10.3322/caac.20114. - DOI - PMC - PubMed
    1. Ho Y-F, Wu M-H, Cheng B-H, Chen Y-W, Shih M-C. Lipid-mediated preferential localization of hypericin in lipid membranes. Biochim Biophys Acta Biomembr. 2009;1788:1287–1295. doi: 10.1016/J.BBAMEM.2009.01.017. - DOI - PubMed
    1. Huntosova V, Alvarez L, Bryndzova L, Nadova Z, Jancura D, Buriankova L, et al. Interaction dynamics of hypericin with low-density lipoproteins and U87-MG cells. Int J Pharm. 2010;389:32–40. doi: 10.1016/J.IJPHARM.2010.01.010. - DOI - PubMed
    1. Agostinis P, Vantieghem A, Merlevede W, de Witte PAM. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 2002;34:221–241. doi: 10.1016/S1357-2725(01)00126-1. - DOI - PubMed

MeSH terms